longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

IN8bio

INAB

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -0.60, within the reasonable range, cheaper than 43.3% of the time in the past 1 years, and the industry ranks 149/602, the industry Median -2.43.

-0.602xP/E
$1.14Stock price
$-1.89Earnings per share
-0.602xP/E
Stock price$1.14Earnings per share$-1.89

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.68x
Typical range
-0.81x–-0.43x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-58.43x148.77%$189.30B
MRNAUSModerna
-23.13x15.47%$72.88B
CSLLYUSCSL Limited
-23.90x--$61.65B
NTRAUSNatera
-292.94x10.38%$56.35B
RVMDUSRevolution Medicines
-23.38x63.53%$41.34B
ROIVUSRoivant Sciences
-103.69x146.49%$27.61B
INSMUSInsmed
-30.14x74.48%$26.38B
BNTXUSBioNTech SE
-12.94x18.23%$25.34B
SMMTUSSummit Therapeutics
-15.95x19.45%$13.66B
BBIOUSBridgebio Pharma
-19.56x28.57%$13.53B
MDGLUSMadrigal Pharma
-36.87x50.86%$11.99B
TWSTUSTwist Bioscience
-79.26x24.61%$10.84B
ARWRUSArrowHead Pharma
-31.72x36,308.30%$10.15B
KYMRUSKymera Therapeutics
-33.88x4.94%$10.15B
IBRXUSImmunityBio
-9.92x152.63%$9.85B
CYTKUSCytokinetics
-10.51x6.37%$9.40B
PCVXUSVaxcyte
-8.25x48.80%$8.78B
ABVXUSAbivax SA
-18.39x20.86%$8.57B
PRAXUSPraxis Precision Medicines
-24.75x3.05%$8.39B
SYREUSSpyre Therapeutics
-53.99x47.81%$8.11B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.